Neuroprotective Effects of Sigma 1 Receptor Ligands on Motoneuron Death after Spinal Root Injury in Mice.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
28 Jun 2021
Historique:
received: 07 06 2021
revised: 22 06 2021
accepted: 24 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 8 2021
Statut: epublish

Résumé

Loss of motor neurons (MNs) after spinal root injury is a drawback limiting the recovery after palliative surgery by nerve or muscle transfers. Research based on preventing MN death is a hallmark to improve the perspectives of recovery following severe nerve injuries. Sigma-1 receptor (Sig-1R) is a protein highly expressed in MNs, proposed as neuroprotective target for ameliorating MN degenerative conditions. Here, we used a model of L4-L5 rhizotomy in adult mice to induce MN degeneration and to evaluate the neuroprotective role of Sig-1R ligands (PRE-084, SA4503 and BD1063). Lumbar spinal cord was collected at 7, 14, 28 and 42 days post-injury (dpi) for immunohistochemistry, immunofluorescence and Western blot analyses. This proximal axotomy at the immediate postganglionic level resulted in significant death, up to 40% of spinal MNs at 42 days after injury and showed markedly increased glial reactivity. Sig-1R ligands PRE-084, SA4503 and BD1063 reduced MN loss by about 20%, associated to modulation of endoplasmic reticulum stress markers IRE1α and XBP1. These pathways are Sig-1R specific since they were not produced in Sig-1R knockout mice. These findings suggest that Sig-1R is a promising target for the treatment of MN cell death after neural injuries.

Identifiants

pubmed: 34203381
pii: ijms22136956
doi: 10.3390/ijms22136956
pmc: PMC8269081
pii:
doi:

Substances chimiques

Neuroprotective Agents 0
Receptors, sigma 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : RTI2018-096386-B-I00
Organisme : Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
ID : CB06/05/1105
Organisme : TERCEL
ID : RD16/0011/0014

Références

Nat Rev Neurol. 2017 Aug;13(8):477-491
pubmed: 28731040
J Neuropathol Exp Neurol. 2018 Jul 1;77(7):577-597
pubmed: 29767748
Neuroscience. 2009 Aug 4;162(1):31-8
pubmed: 19345724
Hand Clin. 2005 Feb;21(1):71-82
pubmed: 15668067
J Neurotrauma. 2009 May;26(5):763-79
pubmed: 19331524
J Comp Neurol. 1994 Apr 1;342(1):35-44
pubmed: 8207127
Neuroscience. 2016 Aug 4;329:213-25
pubmed: 27185485
J Neurotrauma. 2011 May;28(5):831-40
pubmed: 21332255
Clin Neurophysiol. 2011 Aug;122(8):1660-70
pubmed: 21354365
Neurotherapeutics. 2012 Oct;9(4):814-26
pubmed: 22935988
Eur J Neurosci. 2016 Feb;43(3):318-35
pubmed: 26415525
Neurosci Lett. 2014 Jan 24;559:174-8
pubmed: 24334165
Exp Neurol. 1993 Sep;123(1):147-56
pubmed: 8405274
Dev Neurosci. 2015;37(1):66-77
pubmed: 25592862
J Neurotrauma. 2010 Dec;27(12):2273-82
pubmed: 20939695
Hand Clin. 2016 May;32(2):103-17
pubmed: 27094884
Biosci Rep. 2017 Jul 16;37(4):
pubmed: 28667101
Brain. 2019 Feb 1;142(2):295-311
pubmed: 30649249
Br J Pharmacol. 2021 Mar;178(6):1336-1352
pubmed: 32761823
Neuroscience. 2019 Apr 15;404:510-518
pubmed: 30731156
Front Neurol. 2016 Aug 23;7:135
pubmed: 27602018
Cells. 2019 May 21;8(5):
pubmed: 31117227
Brain Res Bull. 2020 Nov;164:184-197
pubmed: 32866558
Neuroscience. 2016 Sep 7;331:148-57
pubmed: 27339730
Sci Rep. 2016 Feb 24;6:21709
pubmed: 26906090
Neuroscience. 2017 Sep 17;359:105-118
pubmed: 28723387
Ann Neurol. 2010 Nov;68(5):639-49
pubmed: 21031579
Elife. 2021 May 11;10:
pubmed: 33973848
Prog Neurobiol. 2007 Jul;82(4):163-201
pubmed: 17643733
Neuroscience. 2013 Oct 10;250:715-32
pubmed: 23896572
Neuropharmacology. 2016 Dec;111:34-46
pubmed: 27567941
Eur J Neurosci. 2003 Oct;18(8):2188-96
pubmed: 14622179
PLoS One. 2013 Oct 18;8(10):e76941
pubmed: 24204710
Neuroscience. 2010 May 5;167(2):247-55
pubmed: 20167253
Sci Rep. 2017 Jan 09;7:40155
pubmed: 28065942
Neurobiol Dis. 2014 Feb;62:218-32
pubmed: 24141020
Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):3
pubmed: 33137196
Pharmacol Res. 2021 Jan;163:105339
pubmed: 33276102
Acta Myol. 2018 May 01;37(1):2-4
pubmed: 30079398
Neuroscience. 2014 Dec 26;283:138-65
pubmed: 25168733
Sci Rep. 2017 Sep 20;7(1):12028
pubmed: 28931824
J Neurotrauma. 2004 Jan;21(1):95-108
pubmed: 14987469
Ann Neurol. 2011 Dec;70(6):913-9
pubmed: 21842496
Exp Neurol. 2014 Nov;261:367-76
pubmed: 24873730
Neuroscience. 2013 Jun 14;240:129-34
pubmed: 23458708
Curr Neurovasc Res. 2006 May;3(2):89-98
pubmed: 16719792
Cell Death Dis. 2018 May 10;9(5):531
pubmed: 29748539
Neurobiol Dis. 2016 Nov;95:168-78
pubmed: 27461051
Cell Death Dis. 2019 Mar 1;10(3):210
pubmed: 30824685
Int J Mol Sci. 2018 Sep 18;19(9):
pubmed: 30231518
Exp Brain Res. 2001 Jul;139(2):216-23
pubmed: 11497064
Eur J Neurosci. 2001 Jan;13(1):113-8
pubmed: 11135009
Exp Neurol. 2010 May;223(1):207-20
pubmed: 19646436
Neurochem Int. 2017 Sep;108:332-342
pubmed: 28522413
Neurology. 2015 Jun 16;84(24):2430-7
pubmed: 26078401
Cell Death Differ. 2011 Oct;18(10):1617-27
pubmed: 21436843

Auteurs

Núria Gaja-Capdevila (N)

Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona, 01893 Bellaterra, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Neus Hernández (N)

Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona, 01893 Bellaterra, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Daniel Zamanillo (D)

Welab, Parc Científic Barcelona, 08028 Barcelona, Spain.

Jose Miguel Vela (JM)

Welab, Parc Científic Barcelona, 08028 Barcelona, Spain.

Manuel Merlos (M)

Welab, Parc Científic Barcelona, 08028 Barcelona, Spain.

Xavier Navarro (X)

Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona, 01893 Bellaterra, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
Institut Guttmann Hospital de Neurorehabilitació, 08916 Badalona, Spain.

Mireia Herrando-Grabulosa (M)

Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona, 01893 Bellaterra, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH